China-based Jiangsu Synthgene Biotechnology Co., Ltd has entered into a partnership with compatriot firm Micor&Nano (Shanghai) Technology Co., Ltd. The collaboration, focused on nucleic acid drugs, aims to provide comprehensive solutions ranging from raw materials to equipment and processes.
Partnership Focus and Objectives
Synthgene, a leading upstream raw material supplier for mRNA vaccines, offers nucleotides, modified nucleotides, chemically capped analogs, and other core raw materials. The company is currently developing upstream core raw materials for small nucleic acid drugs, including phosphoramidite gene monomers and GalNAC. Micor&Nano, on the other hand, specializes in RNA nanodrug delivery solutions, providing a full range of packaging equipment for nucleic acids (including mRNA, siRNA, CRISPR/Cas9, SAM RNA, CircRNA, etc.) from laboratory to industrialization.
Future Outlook
The partnership between Synthgene and Micor&Nano is expected to enhance the development and commercialization of nucleic acid drugs. By combining Synthgene’s expertise in raw material supply with Micor&Nano’s capabilities in RNA nanodrug delivery, the collaboration aims to offer end-to-end solutions for companies in the nucleic acid drug space, ultimately driving innovation and efficiency in the industry.-Fineline Info & Tech
